摘要
目的观察噻托溴铵治疗慢性阻塞性肺疾病急性加重期(AECOPD)临床疗效与安全性。方法选取2010年1月-2011年12月入院的69例AECOPD患者随机分为试验组(A组,n=36)和对照组(B组,n=33),A组在B组常规治疗的基础上吸入噻托溴铵。治疗起始及结束分别观察两组肺功能指标、慢性阻塞性肺疾病评估测试(CAT)评分、血气分析、6分钟步行距离、住院时间及药物不良反应。结果两组均显示出一定的临床效果,A组治疗后肺功能指标、CAT评分、血气分析、6分钟步行距离均优于B组,差异均具有统计学意义(P<0.05)。A组住院时间短于B组(P<0.05),且无严重不良反应。结论 AECOPD患者在常规治疗同时吸入噻托溴铵,疗效显著且临床安全性较高。
Objective To study the clinical efficacy and safety of tiotropium in the treatment of acute exacerbation（AE） of chronic obstructive pulmonary disease（COPD）.Methods Sixty-nine patients admitted to our hospital with AECOPD between January 2010 and December 2011 were randomly divided into experimental group（n=36） and control group（n=33）.Patients in the experimental group used inhaled tiotropium on the basis of routine therapy for the control group.We observed the lung functions,COPD assessment test（CAT） scores,blood gas analysis,6-minute walk distance,days of hospitalization and adverse drug reactions of the two groups of patients before and after treatment.Results Both groups demonstrated some clinical effects after treatment,and the experimental group was superior to the control group in lung functions,CAT scores,blood gas analysis,and 6-minute walk distance with statistically significant differences（P0.05）.The days of hospitalization in the experimental group were shorten than that in the control group（P0.05）,and no serious adverse reactions were observed in the experimental group.Conclusion Inhaled tiotropium with routine therapy has a good clinical curative effect and safety in treating patients with AECOPD.
出处
《华西医学》
CAS
2012年第12期1837-1839,共3页
West China Medical Journal
关键词
噻托溴铵
慢性阻塞性肺疾病
急性加重期
临床疗效
Tiotropium
Chronic obstructive pulmonary disease
Acute exacerbation
Clinical efficacy
